we fund healthy lifespan extension
Portfolio 22
| Date | Name | Website | Total Raised | Location |
| 19.11.2025 | General Co... | generalcontrol.inc | - | - |
| 19.11.2025 | Skeletalis | skeletalis.bio | $8M | - |
| 11.11.2025 | Aerska | aerska.com | $60M | Ireland |
| 11.11.2025 | until | untillabs.com | $58M | United Sta... |
| - | Conception | conception.bio | - | United Sta... |
| - | Next | generalproximity.bio | - | - |
| - | ALX Oncolo... | alxoncology.com | $105M | United Sta... |
| - | SPRING DIS... | springdiscovery.com | - | - |
| - | Arda Thera... | ardatx.com | $43M | - |
| - | FAUNA | faunabio.com | $13.1M | United Sta... |
Show more
Mentions in press and media 11
| Date | Title | Description |
| 17.02.2026 | Canine Longevity Pioneer Loyal Secures $100M for Groundbreaking Anti-Aging Drug | Loyal, a San Francisco-based animal health company, secured $100M in Series C funding. This injection brings total investment past $250M. The capital propels LOY-002, a pioneering prescription drug. LOY-002 extends senior dogs' healthy life... |
| 17.02.2026 | Irish Biotech Aerska Secures $39M for Brain Shuttle RNA Medicines | Aerska, an Irish biotech firm, secured a $39 million Series A funding round. This significant investment will propel its proprietary brain shuttle technology. The platform targets challenging neurological diseases. It delivers RNA medicines... |
| 12.02.2026 | Loyal: $100 Million Series C Raised To Advance First Canine Longevity Drug | Loyal, a San Francisco–based clinical-stage animal health company developing lifespan extension drugs for dogs, has raised $100 million in Series C funding to support the advancement of its lead program, LOY-002, and move closer to market r... |
| 12.02.2026 | Aerska: $39 Million Series A Raised For Advancing Brain Shuttle RNA Medicines | Aerska, a biotechnology company developing brain shuttle technology to deliver RNA medicines to the central nervous system, has closed a $39 million Series A financing led by EQT Dementia Fund and age1, with participation from Iaso Ventures... |
| 11.02.2026 | Loyal Raises $100M in Series C Funding | Loyal, a San Francisco, CA-based clinical-stage animal health company, raised $100M in Series C funding. The round was led by age1 with participation from Baillie Gifford alongside existing investors. The raise brought the total amount to o... |
| 01.10.2025 | Irish biotech Aerska raises $21m to tackle neurological diseases | Irish biotech start-up Aerska has raised $21m (€19.5m) in seed funding to advance new genetic medicines aimed at treating and preventing neurological diseases such as Alzheimer’s and Parkinson’s. The company, founded by Irish entrepreneur J... |
| 28.09.2023 | age1 Closes $35 Million To Invest In Longevity Biotech Companies | age1 – a VC firm catalyzing the next generation of founder-led longevity biotech companies – recently launched to build a community of visionaries advancing new therapeutics, tools, and technologies targeting aging and age-related disease. ... |
| 19.09.2023 | age1 Launches to Back Longevity Biotech Companies | age1, a San Francisco, CA-based venture capital firm investing in the next generation of founder-led longevity biotech companies, officially launched. The firm, which held an initial closing for $35m, will invest in entrepreneurs advancing ... |
| 15.10.2018 | 'To them it was a science fiction story': A VC who's been investing in anti-aging research for 7 years explains why investors are starting to pour hundreds of millions into a field they had previously... | YouTube/Hello Tomorrow Longevity Fund's Laura Deming. Advertisement When Laura Deming launched the Longevity Fund seven years ago, there weren't many investments going into experimental treatments aimed at helping us live healthier and long... |
| 15.09.2018 | 40 AND UNDER: The Silicon Valley biotech stars who are backing startups aiming to cure disease, prolong life, and fix the food system | This story is available exclusively to Insider subscribers. Become an Insider and start reading now. Putting millions of dollars into bold new technologies can be a delicate business when lives hang in the balance. But every day some of the... |
Show more